Medium- to Long-Term Growth Strategy 2026
Filed with TSE · · 2 pages · English
Rohto Pharmaceutical Co., Ltd. on 6ix
In the deck
Earlier from Rohto Pharmaceutical
- バージャー病、膠原病により生じる難治性虚血性（非動脈硬化性）下肢潰瘍に対するRE-01細胞治療の第II相医師主導治験を開始
- Notice Regarding the Status of Repurchase of Shares and Completion of Repurchase
- Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases
- Notice Regarding the Status of Repurchase of Shares
- Notice Regarding Voluntary Recall of Vietnamese-Made Eye Drops in the United States
Later from Rohto Pharmaceutical
- Medium- to Long-Term Growth Strategy 2026,October 5, 2026
- Notice Regarding Partial Corrections to “Medium- to Long-Term Growth Strategy 2026”
Follow Rohto Pharmaceutical into a list and get an email when it puts out news.
Follow Rohto Pharmaceutical